Insider Buying: Indivior (NASDAQ:INDV) Director Buys $27,427.25 in Stock

Indivior PLC (NASDAQ:INDV) Director Keith Humphreys acquired 775 shares of Indivior stock in a transaction dated Monday, January 5th. The stock was bought at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the purchase, the director directly owned 5,802 shares in the company, valued at $205,332.78. This represents a 15.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Indivior Stock Performance

NASDAQ INDV opened at $35.44 on Friday. The business’s fifty day moving average is $34.16 and its 200 day moving average is $25.88. Indivior PLC has a fifty-two week low of $7.62 and a fifty-two week high of $38.00. The company has a market capitalization of $4.43 billion, a PE ratio of 38.52 and a beta of 0.75.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The business had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. On average, sell-side analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 price target (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Northland Securities set a $40.00 target price on shares of Indivior in a report on Friday, October 31st. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Indivior has a consensus rating of “Buy” and a consensus target price of $32.71.

Hedge Funds Weigh In On Indivior

Several institutional investors have recently bought and sold shares of the stock. CWM LLC bought a new stake in Indivior in the 3rd quarter valued at $25,000. Quarry LP bought a new position in shares of Indivior during the 3rd quarter valued at about $26,000. GAMMA Investing LLC grew its position in shares of Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Indivior during the second quarter valued at about $26,000. Finally, Plato Investment Management Ltd bought a new stake in shares of Indivior in the third quarter worth about $52,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.